Value Bridge — ASPIRUS RHINELANDER HOSPITAL
Current $-0M → Target $-9M (+$-9.3M)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-0.0M
Current EBITDA
$-9.3M
Target EBITDA
+$-9.3M
Total Uplift
7
Value Levers
EBITDA Bridge — 7 Lever Model
Each lever shows gross impact, probability of achievement, and probability-weighted value.
Denial Rate Reduction
$-0.0M
AR Acceleration
$-1.6M
Coding Accuracy Uplift
$-1.8M
Payer Mix Optimization
$-4.4M
Cost to Collect Reduction
$-1.5M
Clean Claim Improvement
$-1.1M
Volume & Rate Growth
$-7.3M
What This Means
The 7-lever model projects a 0% EBITDA uplift from $-0M to $-9M. The highest-impact lever is Volume & Rate Growth at $-2.9M probability-weighted.
IC talking point: "We see $-9M in annual EBITDA improvement, primarily from volume & rate growth. At an 11x multiple, this represents $-103M in equity value creation."